Raymond James: Villages Farms Worth Upwards Of $27 Following Full Pure Sunfarms Ownership

Today, analyst Rahul Sarugaser from Raymond James sent out a note to investors about Village Farms (TSX: VFF) (NASDAQ: VFF), upgrading their 12-month price target to U$14 from U$11 and reiterating their Outperform 2 recommendation. The headline reads “4-5x Upside from $5 to $17-$27 Under PSF Acquisition Scenarios | Model Update.”

Rahul says that Village Farms has set themselves up to acquire an even larger majority stake, if not a 100% ownership, in the Pure SunFarms joint venture that it currently owns 58.7% of. Therefore Rahul has been proactive and modeled this hypothetical acquisition and states for Village Farm to purchase up to the remaining 41.3% of the company, it would cost them anywhere between $25 and $300 million.

Raymond James says that Pure SunFarms will capture “a 13% share of Canada’s adult-use market through 2024”, which is then stated “as the base case, which, in turn, derives a potential VFF share price of $17.00.” Raymond James then assumes that with this 100% ownership of Pure SunFarms, Village will be more motivated to hit their target of 20% market share of the Canadian cannabis market, which in turn enables the share price of Village to hit a hypothetical $27 per share.

Selkirk Copper Mines — sponsored Sponsored · Selkirk Copper Mines

There are a lot of moving parts in this hypothetical situation and for that reason Sarugaser made a matrix to justify the valuation estimates. The matrix shows the estimated share price of Village for every additional 10% they own per every $25 million extra in shares they issue to pay for the purchase of Pure SunFarms.

There are then three different columns for caputring 13%, 16% and 20% of the Canadian cannabis market as a whole. Below you can see the hypothetical matrix. As you can see in Sarugaser’s model, if Village Farms has to pay more than $100 million for the 41.3% additional ownership, Village’s hypothetical share price will go as low as $12 – $19 per share, rather than their much rosier $17-$27.

There are currently six analyst recommendations and price targets on Village Farms. All six analysts have buy ratings. The mean 12-month price target is C$14.96, with the highest target coming from Douglas Cooper of Beacon Securities with a C$28 price target, or a 328% upside. The lowest price target is C$8 from Eric Des Lauriers of Craig Hallum, which represents a 23% upside.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

8 Mining Stocks Our Viewers Asked Us to Review | Sept 14th-18th

Canada Is Finally Fast-Tracking New Mines | John Passalacqua – First Phosphate

Gold & Silver Just Added $2 Billion to This Project | Aya Gold – Bourmadine PEA

Recommended

Mercado Minerals Signs LOI for La Franca, Adding 750 Metres of Undrilled Vein at Zamora

Goliath Hits Visible Gold In Bonanza Zone Step-Outs, Drills 9.12 g/t Gold Equivalent Over 11.27 Metres

Related News

Alamos Gold Sees Canaccord Lift Rating To Buy After Q1 Results

This past week Alamos Gold Inc. (TSX: AGI) reported its first quarter financial results. The...

Saturday, April 30, 2022, 01:16:00 PM

Ayr Strategies Price Target Upgraded By Canaccord, Echelon Wealth Following Second Quarter Reporting

Last week, Ayr Strategies (CSE: AYR.A) reported their second-quarter financials and reached an agreement to...

Saturday, August 29, 2020, 01:39:00 PM

Curaleaf: Canccord Slashes Price Target, Anticipates Headwinds For 2022

Earlier this month, Curaleaf Holdings, Inc. (CSE: CURA reported its fourth quarter and full year...

Monday, March 14, 2022, 09:27:00 AM

Lundin Mining Downgraded By Canaccord Due To Candelaria Mine Concerns

Lundin Mining Corporation (TSX: LUN) reported its second quarter financials on July 28. The company...

Friday, August 6, 2021, 11:54:00 AM

Antibe: Canaccord Cuts Price Target From $5.00 To $1.20 After Drug Pivot

In early August, Antibe Therapeutics Inc. (TSX: ATE) announced that they have paused their study...

Monday, October 18, 2021, 11:31:00 AM